Maximum quantity allowed is 999
Please select the quantity
CAS RN: 143112-51-0 | 제품번호: A5563
(R)-(-)-NBD-APy [=(R)-(-)-4-Nitro-7-(3-aminopyrrolidin-1-yl)-2,1,3-benzoxadiazole] [HPLC Labeling Reagent for e.e. Determination]
순도/분석 방법: >98.0%(HPLC)
동의어의:
- (R)-(-)-4-Nitro-7-(3-aminopyrrolidin-1-yl)benzofurazan
- (R)-(-)-4-Nitro-7-(3-aminopyrrolidin-1-yl)-2,1,3-benzoxadiazole
제품문서:
•본 제품의 재고는 일본 본사의 재고입니다. 주문시, 5일안에 실험실까지 도착됩니다.
•본건의 원가격은 한국 대리점의 예상 판매가격입니다.자세한 정보가 필요하시면 연락해 주십시오.( SEJIN CI Co., Ltd. (한국총대리점) 전화 : 02-2655-2480 이메일 : sales@sejinci.co.kr)
•보관 조건은 예고없이 변경 될 수 있습니다. 제품 보관 조건의 최신 자료는 홈페이지에 기재되어 있으니 양해 부탁드립니다.
•본건의 원가격은 한국 대리점의 예상 판매가격입니다.자세한 정보가 필요하시면 연락해 주십시오.( SEJIN CI Co., Ltd. (한국총대리점) 전화 : 02-2655-2480 이메일 : sales@sejinci.co.kr)
•보관 조건은 예고없이 변경 될 수 있습니다. 제품 보관 조건의 최신 자료는 홈페이지에 기재되어 있으니 양해 부탁드립니다.
| 제품번호 | A5563 |
Purity/Analysis Method
|
>98.0%(HPLC) |
| M.F. / M.W. | C__1__0H__1__1N__5O__3 = 249.23 |
| 물리적 상태 (20 ℃) | Solid |
보관 조건
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
용기
|
100MG-Glass Bottle with Plastic Insert (이미지 보기) |
| CAS RN | 143112-51-0 |
| PubChem Substance ID | 87563180 |
| MDL 번호 | MFCD00191510 |
규격표
| Appearance | Orange to Brown to Dark red powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Optical purity(LC) | min. 99.0 ee% |
| Effect test of HPLC derivatization | Effective as labeling agent fo Ibuprofen |
| NMR | confirm to structure |
물성치(참고치)
| 비율 광학 회전 [α]D | -13° (C=0.2,CH3CN) |
GHS
| 픽토그램 |
|
| 신호 워드 | Warning |
| 위험물 및 유해 등록 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| 주의 사항 | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
법규 정보
운송 정보
| HS 번호* | 2934.99-000 |
Application
HPLC Labeling Reagent for Chiral Carboxylic Acids
The compound 1 is an optically active HPLC fluorescence labeling reagent, which has a 2,1,3-benzoxadiazole skeleton and an amino group, and is used for optical purity determination of carboxylic acids. Labeling of racemic carboxylic acids can be done by using a mild condition such as the Mukaiyama-Corey method, and produces diastereomers without inducing racemization. These diastereomers can be separated by reversed phase HPLC, and an excellent chromatogram can be obtained by fluorescence detection at the excitation and emission wavelengths of 470 nm and 540 nm, respectively. Since their excitation and fluorescence wavelengths are at longer wavelengths, detection has less interference by contaminants. A highly sensitive detection can be done by using laser induced fluorescence detector.

Application example:2)
Add 0.1 mL of 10 mM labeling reagent 1 / acetonitrile solution, 0.25 mL of 2 µM carboxylic acid / acetonitrile solution, and 0.15 mL of 10 mM 2,2’-dipyridyl disulfide-triphenylphosphine / acetonitrile solution to a vessel, and react the mixture at room temperature for 4 h. Use the resultant as an HPLC sample solution.
For example, the detection limit (S/N=2) for naproxen is 15 fmol.
Add 0.1 mL of 10 mM labeling reagent 1 / acetonitrile solution, 0.25 mL of 2 µM carboxylic acid / acetonitrile solution, and 0.15 mL of 10 mM 2,2’-dipyridyl disulfide-triphenylphosphine / acetonitrile solution to a vessel, and react the mixture at room temperature for 4 h. Use the resultant as an HPLC sample solution.
For example, the detection limit (S/N=2) for naproxen is 15 fmol.
TCI Products Pamphlet
HPLC Labeling Reagents ( PDF 10MB )
HPLC Labeling Reagents ( PDF 10MB )
References
- 1)T. Toyo'oka, M. Ishibashi, T. Terao, Analyst 1992, 117, 727.

- 2)T. Toyo'oka, M. Ishibashi, T. Terao, J. Chromatogr. 1992, 625, 357.

PubMed Literature
제품기사
제품문서 (분석 차트를 제공하지 못할 수도 있으니 양해 바랍니다.)
